Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Saved in:
| Title: | Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. |
|---|---|
| Authors: | Spigel, David R.1,2 dspigel@tnonc.com, Burris, Howard A.1,2, Greco, F. Anthony1,2, Shih, Kent C.1,2, Gian, Victor G.1,2, Lipman, Andrew J.1,3, Daniel, Davey B.1,4, Waterhouse, David M.5, Finney, Lindsey1, Heymach, John V.6, Hainsworth, John D.1,2, Burris, Howard A 3rd7,8 (AUTHOR) |
| Source: | Cancer (0008543X). Jun2018, Vol. 124 Issue 11, p2355-2364. 10p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
